These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 2055814)

  • 41. The contribution of beta-lactamases to beta-lactam resistance in Bacteroides fragilis.
    Simpson IN; Page CD; Harper PB
    J Antimicrob Chemother; 1982 Jan; 9(1):29-45. PubMed ID: 6977524
    [No Abstract]   [Full Text] [Related]  

  • 42. In-vitro susceptibility of the Bacteroides fragilis group to cefoperazone, ampicillin, ticarcillin and amoxycillin combined with beta-lactamase inhibitors.
    Barry AL; Jones RN; Packer RR
    J Antimicrob Chemother; 1986 Jan; 17(1):125-7. PubMed ID: 3005222
    [No Abstract]   [Full Text] [Related]  

  • 43. Antibiotic susceptibility of anaerobic bacteria with special reference to Bacteroides fragilis.
    Dornbusch K; Nord CE; Olsson-Liljeqvist B
    Scand J Infect Dis Suppl; 1979; (19):17-25. PubMed ID: 37593
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Studies on beta-lactamase in Bacteroides fragilis.
    Nord CE; Dornbusch K; Olsson B
    Infection; 1980; 8 Suppl 2():S167-70. PubMed ID: 6969692
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Multicenter survey of the changing in vitro antimicrobial susceptibilities of clinical isolates of Bacteroides fragilis group, Prevotella, Fusobacterium, Porphyromonas, and Peptostreptococcus species.
    Aldridge KE; Ashcraft D; Cambre K; Pierson CL; Jenkins SG; Rosenblatt JE
    Antimicrob Agents Chemother; 2001 Apr; 45(4):1238-43. PubMed ID: 11257040
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Susceptibilities of anaerobic gram-negative bacilli to thirteen antimicrobials and beta-lactamase inhibitor combinations.
    Hill GB; Ayers OM; Everett BQ
    J Antimicrob Chemother; 1991 Dec; 28(6):855-67. PubMed ID: 1816182
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Bacteroides fragilis group in non-diarrheal human feces and its antimicrobial susceptibility].
    Rodríguez E; Gamboa MM; Rodríguez C; Vargas P
    Rev Esp Quimioter; 2006 Dec; 19(4):357-62. PubMed ID: 17235405
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Antibiotics of choice against Bacteroides fragilis.
    Bittner J; Voinescu V; Munteanu V; Antohi M; Ardeleanu J
    Arch Roum Pathol Exp Microbiol; 1982; 41(3):213-8. PubMed ID: 7159211
    [No Abstract]   [Full Text] [Related]  

  • 49. The antimicrobial susceptibility patterns of the Bacteroides fragilis group in the United States, 1987.
    Cornick NA; Cuchural GJ; Snydman DR; Jacobus NV; Iannini P; Hill G; Cleary T; O'Keefe JP; Pierson C; Finegold SM
    J Antimicrob Chemother; 1990 Jun; 25(6):1011-9. PubMed ID: 2370237
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Factors contributing to resistance to beta-lactam antibiotics in Bacteroides fragilis.
    Olsson B; Dornbusch K; Nord CE
    Antimicrob Agents Chemother; 1979 Feb; 15(2):263-8. PubMed ID: 426517
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Bacteroides fragilis group: trends in resistance.
    Fille M; Mango M; Lechner M; Schaumann R
    Curr Microbiol; 2006 Feb; 52(2):153-7. PubMed ID: 16450067
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Antibiotic susceptibility of anaerobic bacteria isolated in Johannesburg.
    van der Westhuyzen I; Chalkley LJ
    S Afr Med J; 1992 Nov; 82(5):314-7. PubMed ID: 1448710
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Resistance trends of Bacteroides fragilis group over an 8-year period, 1997-2004, in Korea.
    Roh KH; Kim S; Kim CK; Yum JH; Kim MS; Yong D; Lee K; Kim JM; Chong Y
    Korean J Lab Med; 2009 Aug; 29(4):293-8. PubMed ID: 19726890
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Susceptibility trends of Bacteroides fragilis group and characterisation of carbapenemase-producing strains by automated REP-PCR and MALDI TOF.
    Treviño M; Areses P; Peñalver MD; Cortizo S; Pardo F; del Molino ML; García-Riestra C; Hernández M; Llovo J; Regueiro BJ
    Anaerobe; 2012 Feb; 18(1):37-43. PubMed ID: 22261518
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A comparative study of the activity of first and second generation cephalosporins and their combinations with beta-lactamase inhibitors against Bacteroides fragilis.
    Martin MA; Liebana J; Castillo AM; Gutierrez J; Piédrola G
    Microbios; 1991; 67(272-273):195-202. PubMed ID: 1779879
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Properties of a new penicillinase type produced by Bacteroides fragilis.
    Sato K; Matsuura Y; Inoue M; Mitsuhashi S
    Antimicrob Agents Chemother; 1982 Oct; 22(4):579-84. PubMed ID: 6983857
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Induction of beta-lactamase production in the anaerobic microflora by cefoxitin.
    Stark C; Edlund C; Hedberg M; Nord CE
    Clin Infect Dis; 1995 Jun; 20 Suppl 2():S350-1. PubMed ID: 7548595
    [No Abstract]   [Full Text] [Related]  

  • 58. Increased resistance to cefoxitin and cefotetan among Bacteroides fragilis isolates from abdominal sources in patients undergoing surgery.
    Ehrenkranz NJ; Alfonso B
    Clin Infect Dis; 1993 Dec; 17(6):1080-2. PubMed ID: 8110948
    [No Abstract]   [Full Text] [Related]  

  • 59. Absence of tolerance to cefoxitin in anaerobic bacteria.
    Goldstein EJ; Kwok YY; Sutter VL
    Antimicrob Agents Chemother; 1981 Jul; 20(1):146-8. PubMed ID: 7283412
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The comparative activity of cefsulodin against anaerobic bacteria of clinical interest: synergy with cefoxitin.
    Watt B; Brown FV
    J Antimicrob Chemother; 1981 Mar; 7(3):269-78. PubMed ID: 6974166
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.